Zlepší monitorování krevních hladin adherenci a efekt léčby u schizofrenie?

Warning

This publication doesn't include Institute of Computer Science. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.
Title in English Would therapeutic drug monitoring improve adherence and efficaccy of treatment in schizophrenia?
Authors

ČEŠKOVÁ Eva

Year of publication 2011
Type Article in Periodical
Magazine / Source Psychiatrie pro Praxi
MU Faculty or unit

Central European Institute of Technology

Citation
Field Psychiatry, sexuology
Keywords therapeutic drug monitoring; pharmacoresistance; schizophrenia; clozapine; plasma levels
Description Therapeutic drug monitoring (TDM) is considered to be a valid tool for optimization of pharmacotherapy, however, in clinical practice is rarely used. TDM may help to answer the questions important for a choice of treatment strategy, e.g. whether the patient takes the drug and whether the drug is taken in a sufficient dose. The most common causes of nontherapeutic range of plasma levels include non-adherence and pharmacokinetic interaction. Clozapine still represents the gold standard in the treatment of pharmacoresistant schizophrenia and optimal plasma levels for acute and maintenance clozapine treatment are well known. Literature and our experience show that TMD in clinically defined patients subgroups is clinically advantageous.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info